{"id":"W2283246712","doi":"10.1007/s10637-015-0313-8","title":"A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Adverse effect; Pharmacology; Tolerability; Internal medicine; Nausea; Rash; Toxicity; Gastroenterology; Urology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000340218,0.0002153082,0.0002964437,0.0001048219,0.00003304573,0.00001985218,0.000179346,0.0001619484,0.00001214115],"category_scores_gemma":[0.0004817833,0.0002240484,0.00007055231,0.0001921486,0.0002636776,0.00001941613,0.00008384723,0.0001351695,0.000005519363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005652922,"about_ca_system_score_gemma":0.001107078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001199302,"about_ca_topic_score_gemma":0.00003877187,"domain_scores_codex":[0.9983574,0.00008572473,0.0005126497,0.0004257781,0.0003627329,0.000255746],"domain_scores_gemma":[0.9989807,0.00005048342,0.0002374968,0.0002548326,0.0001469332,0.0003295591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01081158,0.0005224905,0.001431408,0.00004757429,0.00007185458,0.0000139272,0.001253077,0.001209635,0.9629455,0.0005462834,0.01556524,0.005581494],"study_design_scores_gemma":[0.1248403,0.00387876,0.0004130129,0.0002034736,0.00004046552,0.00003303082,0.0003609947,0.0005977941,0.8341544,0.008282389,0.02651532,0.0006800815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970665,0.0008376669,0.00007578145,0.0005542978,0.0003608962,0.0003724682,0.00006747463,0.00001615323,0.0006487916],"genre_scores_gemma":[0.9956735,0.00002283976,0.002136784,0.0004840297,0.0009435471,0.000050705,0.0001729222,0.00003219602,0.0004834945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.128791,"threshold_uncertainty_score":0.9136431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02692852058864713,"score_gpt":0.3128435058557544,"score_spread":0.2859149852671073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}